UnitedHealth (UNH) Stock Still Looks Like A Bargain As Forecasts Rise

UnitedHealth Group stock has delivered a strong 57.1% return over the past year, and the current valuation checks now point to a mixed picture rather than an obvious bargain or clear overpricing.

• Over the last 12 months, a 57.1% gain has pushed UnitedHealth Group firmly back into focus for investors weighing how much of the recovery is already reflected in the share price.
• Recent earnings strength and operational improvements can support expectations for healthier margins, while the expanded antitrust investigation and broader regulatory scrutiny may cap how much investors are willing to pay for those cash flows.
• On Simply Wall St's broader checks, UnitedHealth Group scores 4 out of 6 on valuation, which points to some supportive signals alongside others that are less clearly cheap.

The issue now is whether UnitedHealth Group's current share price still offers enough valuation support after this rebound in returns.

UnitedHealth Group delivered 57.1% returns over the last year. See how this stacks up to the rest of the Healthcare industry.

Is UnitedHealth Group Still Cheap on Earnings?

The P/E ratio is a useful lens for UnitedHealth Group because earnings remain a core anchor for how investors value large, mature healthcare insurers.

UnitedHealth Group currently trades on a P/E of 28.1x, above the broader Healthcare industry average of 25.7x, but below the peer average of 39.6x. The fair P/E multiple implied by Simply Wall St's model, which adjusts for factors such as the company’s scale, profitability profile and sector risks, stands at 41.3x. This is comfortably above where the stock trades today.

Despite the recent lift in sentiment following stronger second quarter results and a higher 2026 earnings forecast, the present earnings multiple still sits at a discount to this fair ratio. On this framework, the stock does not need to move toward typical peer levels for the model to see value support in UnitedHealth Group at its current P/E.

On a P/E basis, UnitedHealth Group appears undervalued relative to the fair multiple implied by its fundamentals and risk profile.

See what the numbers say about this price — find out in our valuation breakdown.

The UnitedHealth Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for UnitedHealth Group are designed to link this valuation puzzle to concrete expectations by explaining what kind of earnings, margin and growth profile would need to occur for the stock to be worth significantly more or less than today's price on the Community page. Rather than relying on a single multiple or model output, each Narrative details its underlying assumptions so you can compare them with UnitedHealth Group's results as they are reported.

Community views on UnitedHealth Group sit far apart, with one side seeing deep value and the other seeing a valuation that already bakes in a lot of good news.

Bull case: 30% undervalued

"UnitedHealth maintains a leading position in the U.S. healthcare industry, supported by durable competitive advantages that reinforce its market dominance."

Read the full Bull Case to see why UnitedHealth Group could be undervalued

Bear case: roughly fairly valued

"Challenges with Medicare, CMS risk model execution, and external funding pressures adversely impact UnitedHealth Group's financial performance and margins."

Read the full Bear Case to see why UnitedHealth Group could be overvalued

Do you think there's more to the story for UnitedHealth Group? Head over to our Community to see what others are saying!

The Bottom Line

UnitedHealth Group screens as undervalued on the tailored P/E multiple, suggesting the current price does not fully reflect the earnings profile implied by the fundamentals discussed above. At the same time, the mixed outcome across broader valuation checks argues against treating it as a clear-cut bargain. The crux is whether UnitedHealth Group can sustain the earnings quality and margin resilience that would justify even a modest re rating, while managing the regulatory and antitrust risks that could restrain how far investors are willing to stretch the multiple from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com